Provider review
Hims & Hers Tirzepatide Review
Hims & Hers is reviewed here against a fixed evidence checklist: legal identity, program type, advertised and effective tirzepatide pricing, mandatory fees, dose coverage, pharmacy verification, clinician model, and cancellation terms. Its tirzepatide pricing cannot currently be normalised into a comparable monthly figure. Pharmacy, clinician, and policy fields remain unverified and are shown as pending.
Key takeaways
- Tirzepatide pricing is not published in a form that can be normalised, so this provider is excluded from cost rankings.
- Mandatory fees recorded: Membership fee plus medication.
- Compounding pharmacy, licence, facility type, clinicians, states, and cancellation terms are all unverified and shown as Verification Pending rather than inferred.
- This publication has no financial, affiliate, referral, or sponsorship relationship with this provider.
- Compounded tirzepatide is not FDA approved and is not reviewed by the FDA before sale.
| Provider | Hims & Hers |
|---|---|
| Operating status | Active |
| Program type | Primary national / major telehealth |
| Tirzepatide price (as captured) | Availability is program- and medical-need-dependent; no single universal compounded price used |
| Normalised monthly cost | Verification Pending |
| Mandatory fees | Membership fee plus medication |
| Medication included | No |
| Billing cadence | Monthly membership; medication plan may use multi-month billing |
| Compounding pharmacy | Verification Pending |
| Pharmacy licence | Verification Pending |
| Facility type (503A/503B) | Verification Pending |
| Named clinicians | Verification Pending |
| States served | Verification Pending |
| Dose coverage | Verification Pending |
| Shipping terms | Verification Pending |
| Cancellation policy | Verification Pending |
| Refund policy | Verification Pending |
| Auto-renewal terms | Verification Pending |
| Publisher relationship | None — no financial, ownership, affiliate, referral, or sponsorship relationship |
| Evidence source | Official provider |
| Source confidence | Moderate |
| Price verified | 2026-07-20 |
What is the verdict on this provider?
Hims & Hers publishes tirzepatide pricing in a form this site cannot normalise into a comparable monthly figure (Advertised figure covers medication only; mandatory care or membership fees billed separately), so it is excluded from cost rankings. That is a comparability limitation, not a judgement about the service.
What does tirzepatide actually cost at Hims & Hers?
Hims & Hers does not publish tirzepatide pricing in a form that can be normalised into a comparable monthly figure. Captured text: Availability is program- and medical-need-dependent; no single universal compounded price used.
Because the effective recurring cost cannot be computed from public information, this provider is excluded from cost rankings. Exclusion reflects disclosure, not service quality.
What does the captured source actually state?
| Field | Text as captured from the provider's own page |
|---|---|
| Tirzepatide pricing, as published | Availability is program- and medical-need-dependent; no single universal compounded price used |
| Semaglutide pricing, as published | Availability is program- and medical-need-dependent; no single universal compounded price used |
| Fee structure, as published | Membership fee plus medication |
| Medication inclusion, as published | No |
| Billing cadence, as published | Monthly membership; medication plan may use multi-month billing |
| Evidence type | Current advertised starting prices |
| Capture caveat | Product, formulation, state availability, and recurring price vary. Verify exact checkout and renewal amount. |
How should the Hims & Hers pricing structure be read?
Hims & Hers publishes multi-month or prepaid options alongside any monthly rate. Committed tiers lower the advertised monthly figure but concentrate financial risk: if treatment stops early — and gastrointestinal effects end treatment for a measurable share of people — the money already paid is governed by cancellation and refund terms that are unverified here.
The same source also publishes semaglutide pricing, which is useful context: a provider pricing both drugs allows a switch without changing provider, though the two are not interchangeable and any change is a prescriber decision.
Source confidence for this record is recorded as Moderate, which is why the figures above are presented as captured text rather than asserted as the current price.
What has not been verified?
What should you confirm before enrolling?
- The recurring price after any introductory or first-month rate, in writing.
- Every mandatory fee: membership, consultation, shipping, and any dose-related surcharge.
- Which compounding pharmacy dispenses, its state licence number, and whether it is 503A or 503B.
- What happens to the price when your dose increases.
- The cancellation method, notice period, and whether prepaid months are refundable.
- Whether the plan auto-renews and how to stop it.
- That a licensed clinician reviews your intake and is reachable for side-effect questions.
What are the alternatives?
Primary source: Hims & Hers pricing page · captured 2026-07-20. Product, formulation, state availability, and recurring price vary. Verify exact checkout and renewal amount.
| Group | Verified | Required for full review |
|---|---|---|
| Pricing fields held | 2 | 5 |
| Pharmacy fields held | 0 | 4 |
| Policy fields held | 0 | 4 |
Why is this provider not ranked on cost?
| Test | Result for this provider |
|---|---|
| Recurring price stated | Yes |
| Medication included | No |
| All mandatory fees confirmed | No |
| Classification | medication only |
| Published reason | Advertised figure covers medication only; mandatory care or membership fees billed separately |
What is Hims & Hers's status after the compounding change?
Hims & Hers was captured on 2026-07-20 advertising compounded tirzepatide. That capture predates nothing — it is recent — but the legal basis for the product it describes changed before it was taken. Compounding of tirzepatide was permitted only while the drug sat on the FDA shortage list. The shortage was declared resolved on 2 October 2024 and reaffirmed by declaratory order on 19 December 2024, and enforcement discretion ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities.
This site therefore treats Hims & Hers's captured pricing as a dated historic record of what the compounded market charged, not as a live offer to compare against others. If Hims & Hers continues to advertise compounded tirzepatide, the useful question is not whether the price is competitive but what legal basis the product is supplied under and which state-licensed pharmacy dispenses it. Neither is verified in this record.
| Question | Position for Hims & Hers | How this site treats it |
|---|---|---|
| Was compounded tirzepatide advertised at capture? | Yes | Recorded as a dated historic figure |
| Operating status at capture | Active | Reported as captured; not re-verified since |
| Legal basis for continued compounded supply | Not disclosed in the captured source | Verification Pending — not inferred |
| Dispensing pharmacy identity | Not disclosed | Verification Pending |
| Whether approved products are now offered | Not established in this record | Verification Pending — ask the provider directly |
How was Hims & Hers's pricing classified?
Every provider on this site passes through the same four-part price test before it can appear in a cost ranking. The test asks whether the captured source states a recurring price, whether medication is included in that price, whether every mandatory fee is identified, and whether the figure describes the standard subcutaneous injection rather than an alternative formulation. Hims & Hers is assessed below against each part in turn.
| Test | Result for this provider | Why it matters |
|---|---|---|
| A recurring price is stated | Yes | Availability is program- and medical-need-dependent; no single universal compounded price used |
| Medication is included in that price | No | Determines whether the figure is the whole cost or only part of it |
| Every mandatory fee is identified | Membership fee plus medication | A separate recurring membership or care fee changes the real monthly outlay |
| The figure describes the standard injection | not applicable | Microdose, ODT, sublingual and troche preparations are not comparable with an injection |
| Classification result | medication only | Advertised figure covers medication only; mandatory care or membership fees billed separately |
Hims & Hers does not pass, and the reason is specific: Advertised figure covers medication only; mandatory care or membership fees billed separately. This is a statement about disclosure, not about service quality or value. A provider may be excellent and still publish pricing in a form that cannot be normalised — and equally, a provider that publishes a complete price may not be the right choice on any other dimension. The exclusion means only that a like-for-like cost comparison is not currently possible.
How does Hims & Hers compare with the providers that can be ranked?
Hims & Hers cannot be placed on this axis, so no position is assigned. For reference, the providers that can be ranked run from TRYM Health at $125 per month to Eden at $298. Any figure Hims & Hers advertises should be compared against those only after confirming directly what it includes — specifically whether medication is in the price and what recurring fees are charged on top.
| Provider | Verified all-in monthly | Basis of the figure |
|---|---|---|
| TRYM Health | $125 | complete published commitment ladder for the standard injection: medication included, no separate membership o |
| NexLife | $186 | complete published commitment ladder for the standard injection: medication included, no separate membership o |
| Fridays | $240 | advertised monthly rate with medication included and no separate membership fee |
| Mochi Health | $278 | effective recurring cost: medication plus every mandatory fee, computed from the captured components |
| Eden | $298 | effective recurring cost: medication plus every mandatory fee, computed from the captured components |
What else does Hims & Hers's captured record contain?
The full record held for Hims & Hers is reproduced below. This site publishes the underlying capture rather than only its own summary, so a reader can see exactly what the interpretation rests on and disagree with it if the reading looks wrong.
| Field | Value held for this provider |
|---|---|
| Programme category | Primary national / major telehealth |
| Operating status | Active |
| Tirzepatide pricing, as captured | Availability is program- and medical-need-dependent; no single universal compounded price used |
| Semaglutide pricing, as captured | Availability is program- and medical-need-dependent; no single universal compounded price used |
| Mandatory fees, as captured | Membership fee plus medication |
| Medication inclusion | No |
| Billing cadence | Monthly membership; medication plan may use multi-month billing |
| Evidence type | Current advertised starting prices |
| Capture caveats | Product, formulation, state availability, and recurring price vary. Verify exact checkout and renewal amount. |
| Source | Official provider |
| Source confidence | Moderate |
| Price verified | 2026-07-20 |
Hims & Hers's semaglutide pricing is recorded because the relationship between a provider's semaglutide and tirzepatide pricing is informative on its own. Semaglutide is typically the cheaper of the two in this market, and a provider whose tirzepatide premium is unusually large or unusually small relative to its semaglutide rate is worth asking about — it can reflect different pharmacy sourcing, different dose coverage, or a promotional structure that will not persist. For Hims & Hers the captured semaglutide text reads: Availability is program- and medical-need-dependent; no single universal compounded price used
The capture for Hims & Hers is rated moderate confidence. That rating reflects genuine ambiguity in the source — typically a page that presents a starting figure without stating which dose, formulation, or commitment length it applies to, or that presents different figures on different landing pages. Moderate confidence is why the figure is reported but not ranked.
What should you ask Hims & Hers before enrolling?
These questions are selected against the specific gaps in Hims & Hers's record rather than being a generic checklist. Ask them in writing and keep the reply: a verbal assurance from a sales channel is not a contractual term, and terms are what govern a dispute.
- What is the recurring monthly price after any introductory or first-month rate?
- Is the medication itself included in that price, or billed separately?
- What recurring fees apply on top of the medication, and are any of them waived initially?
- What is the total of medication plus every care or membership charge in a typical month?
- Which compounding pharmacy prepares the medication, and what is its state licence number?
- Is that pharmacy a 503A compounder or a 503B outsourcing facility?
- Does the price change when the dose increases to 10 mg or 15 mg?
- What concentration is dispensed, in mg/mL, and what beyond-use date is assigned?
- How is the plan cancelled, what notice is required, and are prepaid months refundable?
- Does the plan auto-renew, and how is renewal stopped?
- Which licensed clinician reviews the intake, and how are side-effect questions handled?
A provider that answers all of these in writing has demonstrated something meaningful about how it operates. A provider that will not name its compounding pharmacy before payment has also told you something, and it is worth weighing that refusal as evidence in its own right.
Why is this review shorter than the others?
Because the evidence held for Hims & Hers does not support more. Its captured pricing (Advertised figure covers medication only; mandatory care or membership fees billed separately) cannot be reduced to a comparable recurring figure, and its pharmacy, clinician, states, dose-coverage and cancellation fields are all unverified. Writing further would mean inferring facts rather than reporting them.
This site treats a short page as the correct output in that situation. The alternative — padding a review with general commentary that would read identically for any provider — would give an impression of thoroughness the underlying evidence does not justify, and would make it harder for a reader to see which providers have actually disclosed something. The length of this page is itself a finding.
Current approved-product pathways: Zepbound self-pay from $299 per month at the starting dose. Full pathway comparison.
What do the technical terms on this page mean?
Definitions for the 9 technical terms this page uses, including 503A, 503B, auto-renewal, beyond-use date — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| auto-renewal | A term under which a plan renews automatically unless cancelled. Combined with a notice period, it determines how much money is at risk if treatment stops. |
| beyond-use date | The date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| effective monthly cost | The recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking. |
| membership fee | A recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper. |
| mg/mL | Milligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations. |
| subcutaneous | Beneath the skin. Tirzepatide is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm. |
Frequently asked questions
How much does tirzepatide cost at Hims & Hers?
Pricing is not published in a form that can be normalised into a comparable monthly figure, so no cost is asserted here.
Which pharmacy does Hims & Hers use?
Not verified. The compounding pharmacy identity, its state licence, and whether it is a 503A or 503B facility have not been confirmed first-party, so nothing is asserted.
Is Hims & Hers cheaper than other providers?
Only providers whose all-in effective monthly cost can be computed are ranked against each other. See the most affordable page for the eligible set and the excluded records with reasons.
Does Tirzepatide Editorial earn a commission from Hims & Hers?
No. There is no financial, ownership, affiliate, referral, or sponsorship relationship with this or any provider. Outbound links are nofollow and carry only our own analytics parameters.
Is compounded tirzepatide FDA approved?
No. Compounded tirzepatide is not FDA approved and is not reviewed by the FDA for safety, effectiveness, or quality before sale.
Sources for this page
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.